Wealth Enhancement Advisory Services LLC Takes $28,000 Position in Black Diamond Therapeutics, Inc. $BDTX

Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,984 shares of the company’s stock, valued at approximately $28,000.

Several other institutional investors have also bought and sold shares of the stock. AWM Investment Company Inc. bought a new position in Black Diamond Therapeutics in the 1st quarter valued at $775,000. Brown Wealth Management LLC purchased a new stake in Black Diamond Therapeutics during the 1st quarter worth about $155,000. AQR Capital Management LLC purchased a new stake in Black Diamond Therapeutics during the 1st quarter worth about $84,000. Bank of America Corp DE raised its holdings in shares of Black Diamond Therapeutics by 76.7% in the 4th quarter. Bank of America Corp DE now owns 74,719 shares of the company’s stock valued at $160,000 after acquiring an additional 32,422 shares in the last quarter. Finally, Invesco Ltd. grew its stake in Black Diamond Therapeutics by 152.5% in the 1st quarter. Invesco Ltd. now owns 45,989 shares of the company’s stock worth $71,000 after buying an additional 27,777 shares in the last quarter. Institutional investors own 95.47% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BDTX. Raymond James Financial raised Black Diamond Therapeutics to an “outperform” rating and set a $11.00 price objective on the stock in a report on Tuesday, July 1st. Wall Street Zen lowered Black Diamond Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Zacks Research raised Black Diamond Therapeutics to a “strong-buy” rating in a research note on Monday, August 11th. Guggenheim assumed coverage on Black Diamond Therapeutics in a report on Wednesday, September 3rd. They issued a “buy” rating and a $8.00 target price on the stock. Finally, HC Wainwright decreased their price target on Black Diamond Therapeutics from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Black Diamond Therapeutics Stock Down 7.1%

Shares of BDTX opened at $3.80 on Tuesday. The business has a 50-day simple moving average of $3.14 and a two-hundred day simple moving average of $2.50. The stock has a market cap of $216.37 million, a price-to-earnings ratio of 16.52 and a beta of 3.07. Black Diamond Therapeutics, Inc. has a 52 week low of $1.20 and a 52 week high of $4.38.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.06. On average, equities analysts anticipate that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current fiscal year.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.